Literature DB >> 28040756

Current practices in the management of malignant pleural effusions: a survey among members of the European Society of Thoracic Surgeons.

Marco Scarci1, Edward Caruana2, Luca Bertolaccini3, Benedetta Bedetti1, Alessandro Brunelli4, Gonzalo Varela5, Kostas Papagiannopoulos4, Jaroslaw Kuzdzal6, Gilbert Massard7, Enrico Ruffini8, Pierre Emmanuel Falcoz7, Isabelle Opitz9, Hasan Batirel10, Alper Toker11, Gaetano Rocco12.   

Abstract

Objectives: Malignant pleural effusion (MPE) commonly complicates advanced malignancy and their exact management is still undefined. We undertook a survey to determine the current practice among members of the European Society of Thoracic Surgeons (ESTS).
Methods: A cross-sectional survey focused on the current practice of management of MPE was developed by the authors. The questions were outlined after a review of the literature and circulated in an Internet-based survey format.
Results: Computed tomography (125, 92%) and chest X-ray (106, 78%) are the most common imaging modalities performed in the initial evaluation. Video-assisted thoracoscopic surgery for washout and pleurodesis (93, 68%) was reported as the preferred approach to patients with uncomplicated MPE. Sixty-one (45%) of the responding colleagues routinely use large bore chest tubes for draining malignant effusions. Forty-nine (35%) surgeons would not apply suction to the drainage system, whilst 50 (37%) would use -2 kPa or less. Talc (124, 91%) is the most commonly used sclerosing agent for pleurodesis in the context of malignant pleural effusion. The practice of 76 (56%) of the respondents is not informed by any clinical guidelines, whilst 60 (44%) reported adhering to the 2010 British Thoracic Society Pleural Disease Guideline. Seventy-one (52%) declared that the guidance was in need of updating or revision. Conclusions: This survey demonstrates the lacking adoption of the existing clinical guidance in this field, as well as the need for more contemporary guidelines for a better-informed practice. The ESTS Working Group on the management of MPE has been established for this purpose.
© The Author 2016. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Malignant pleural effusion • Survey • ESTS Malignant Pleuralzzm321990 Effusion Working Group

Mesh:

Year:  2017        PMID: 28040756     DOI: 10.1093/icvts/ivw373

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  4 in total

1.  Surgical Decision-Making in Median Neuropathy Associated with Distal Radius Fractures.

Authors:  Sezai Özkan; Chaitanya S Mudgal; Brady T Evans; Colyn J Watkins; Marilyn M Heng; Frank W Bloemers
Journal:  J Wrist Surg       Date:  2019-04-22

Review 2.  Contemporary best practice in the management of malignant pleural effusion.

Authors:  Coenraad F N Koegelenberg; Jane A Shaw; Elvis M Irusen; Y C Gary Lee
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

3.  Viscum pleurodesis is as effective as talc pleurodesis and tends to have less adverse effect.

Authors:  YongJin Chang; DeogGon Cho; KyuDo Cho; MinSeop Cho
Journal:  Support Care Cancer       Date:  2020-03-12       Impact factor: 3.603

4.  Australasian Malignant PLeural Effusion (AMPLE)-3 trial: study protocol for a multi-centre randomised study comparing indwelling pleural catheter (±talc pleurodesis) versus video-assisted thoracoscopic surgery for management of malignant pleural effusion.

Authors:  Deirdre B Fitzgerald; Calvin Sidhu; Charley Budgeon; Ai Ling Tan; Catherine A Read; Benjamin C H Kwan; Nicola Ann Smith; Edward T Fysh; Sanjeevan Muruganandan; Tajalli Saghaie; Ranjan Shrestha; Arash Badiei; Phan Nguyen; Andrew Burke; John Goddard; Morgan Windsor; Julie McDonald; Gavin Wright; Kasia Czarnecka; Parthipan Sivakumar; Kazuhiro Yasufuku; David J Feller-Kopman; Nick A Maskell; Kevin Murray; Y C Gary Lee
Journal:  Trials       Date:  2022-06-27       Impact factor: 2.728

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.